Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03587311
Title Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

endometrioid ovary carcinoma

ovarian serous carcinoma

fallopian tube cancer

peritoneum cancer

Therapies

Anetumab ravtansine + Bevacizumab

Bevacizumab + Paclitaxel

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.